Open AccessRelaxin inhibits cardiac fibrosis and endothelial–mesenchymal transition via the Notch pathway
Author(s) -
Xi Zhou,
Xiao Chen,
Jie Cai,
Ling Zhi Chen,
Yong Gong,
Liang Xing Wang,
Zhan Gao,
Huai Qin Zhang,
Wei Huang,
Hao Zhou
Publication year - 2015
Publication title -
drug design, development and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.964
H-Index - 64
ISSN - 1177-8881
DOI - 10.2147/dddt.s85399
Subject(s) - cardiac fibrosis , umbilical vein , cd31 , vimentin , mesenchymal stem cell , western blot , notch signaling pathway , fibrosis , myocardial fibrosis , human umbilical vein endothelial cell , chemistry , cardiac function curve , relaxin , endocrinology , microbiology and biotechnology , medicine , signal transduction , biology , heart failure , in vitro , immunohistochemistry , receptor , biochemistry , gene
Relaxin (RLX) can prevent cardiac fibrosis. We aimed to investigate the possible mechanism and signal transduction pathway of RLX inhibiting cardiac fibrosis.